Neuromuscular Blocking Effect of Rocuronium on Post-tetanic Count

Phamacokinetic & Pharmacodynamic Analysis of the Neuromuscular Blocking Effect of Single Bolus Administration of Rocuronium on Post-tetanic Count

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0001283

Enrollment

Registered

2014-11-21

Start date

2014-08-18

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : IV administration of Rocuronium, 0.4, 0.8, 1.2mg/kg dose. once.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Adult patients, ASA(American Society of Anesthesiologists) class I-II, undergoing laparoscopic cholecystectomy under general anesthesia are enrolled

Exclusion criteria

Exclusion criteria: Patient's weight exceed 30% of ideal body weight or under 30% of ideal body weight. Neuromuscular disease patient, Renal disease patient, Hepatic disease patient. Patient taking drug that effect neuromuscular transmission. Pregnant woman, Breast-feeding patient, Subject of vulnerability of definition of clinical trial review committee of medical institutions that clinical trials have been conducted

Design outcomes

Primary

Measure	Time frame
PTC	—

Secondary

Measure	Time frame
Plasma concentration of rocuronium	—

Countries

Korea, Republic of

Contacts

Public ContactHyojin Byun

Yonsei University Health System, Severance Hospital

jinoben@naver.com

Outcome results